lunes, 6 de mayo de 2019

How many can benefit from checkpoint inhibitors?

The Readout
Damian Garde

How many can benefit from checkpoint inhibitors?

The response rate to immunotherapy is variable, with general estimates ranging in the 15% to 40% range. Dr. Vinay Prasad, an oncologist at Oregon Health and Science University, has a new study out in JAMA that gauges how many patients get benefit from six different checkpoint inhibitor immunotherapy drugs. The consensus? 
Turns out, even 15% seems a bit optimistic. The 2011 response rate was 0.14 percent, he writes — though the figure is improving. In 2018, Prasad said the estimate percentage of responders is 12.46%. He suggests that further research is needed to explore biomarkers that might maximize the benefit of immunotherapy. 
“The observations in this article are sobering and remind us to keep expectations of [checkpoint inhibitors] realistic,” a companion commentary in JAMA says.

No hay comentarios: